Neurocrine Biosciences Inc
NASDAQ:NBIX
Neurocrine Biosciences Inc
NASDAQ:NBIX
Price:
155.51
USD
0.84%
Market Closed
Market Cap:
15.5B
USD
Add
Note
Why Create Notes?
Capture your thoughts
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Peter Lynch
Track and Analyze Performance
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Continuous Learning and Adaptation
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
Boost Decision Confidence
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Delete Note
Do you really want to delete this note?
This action cannot be undone.
NBIX Alert
Neurocrine Biosciences Inc
155.51
+1.29 (+0.84%)
| 52 Week Range |
87.54
155.51
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
Delete Alert
This alert will be permanently deleted.
Balance Sheet
Balance Sheet Decomposition
Neurocrine Biosciences Inc
Neurocrine Biosciences Inc
| Current Assets | 2.2B |
| Cash & Short-Term Investments | 1.1B |
| Receivables | 728m |
| Other Current Assets | 315.6m |
| Non-Current Assets | 2.1B |
| Long-Term Investments | 1.1B |
| PP&E | 566.2m |
| Intangibles | 35.7m |
| Other Non-Current Assets | 388.8m |
| Current Liabilities | 638m |
| Accounts Payable | 396.8m |
| Accrued Liabilities | 238.8m |
| Other Current Liabilities | 2.4m |
| Non-Current Liabilities | 624.1m |
| Other Non-Current Liabilities | 624.1m |
Balance Sheet
Neurocrine Biosciences Inc
Neurocrine Biosciences Inc
Currency: USD
| Dec-2001 | Dec-2002 | Dec-2003 | Dec-2004 | Dec-2005 | Dec-2006 | Dec-2007 | Dec-2008 | Dec-2009 | Dec-2010 | Dec-2011 | Dec-2012 | Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||||||||||||
| Cash & Cash Equivalents |
164
|
44
|
106
|
61
|
50
|
81
|
100
|
69
|
37
|
54
|
50
|
64
|
45
|
31
|
74
|
83
|
255
|
142
|
112
|
187
|
341
|
263
|
1 032
|
1 076
|
|
| Cash Equivalents |
164
|
44
|
106
|
61
|
50
|
81
|
100
|
69
|
37
|
54
|
50
|
64
|
45
|
31
|
74
|
83
|
255
|
142
|
112
|
187
|
341
|
263
|
1 032
|
1 076
|
|
| Short-Term Investments |
156
|
200
|
347
|
240
|
223
|
102
|
80
|
12
|
16
|
73
|
79
|
109
|
101
|
163
|
305
|
224
|
261
|
509
|
558
|
614
|
371
|
726
|
781
|
843
|
|
| Total Receivables |
10
|
0
|
14
|
8
|
1
|
7
|
0
|
0
|
0
|
5
|
2
|
14
|
0
|
0
|
0
|
0
|
31
|
57
|
127
|
157
|
186
|
350
|
439
|
479
|
|
| Accounts Receivables |
10
|
0
|
14
|
8
|
1
|
7
|
0
|
0
|
0
|
5
|
2
|
14
|
0
|
0
|
0
|
0
|
31
|
57
|
127
|
157
|
186
|
350
|
439
|
479
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Inventory |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
11
|
17
|
28
|
31
|
35
|
38
|
57
|
|
| Other Current Assets |
2
|
3
|
5
|
5
|
5
|
4
|
4
|
1
|
2
|
2
|
2
|
2
|
3
|
4
|
5
|
3
|
8
|
19
|
17
|
30
|
46
|
79
|
98
|
112
|
|
| Total Current Assets |
332
|
248
|
472
|
314
|
279
|
194
|
183
|
81
|
55
|
133
|
133
|
189
|
149
|
198
|
384
|
310
|
555
|
738
|
831
|
1 016
|
973
|
1 454
|
1 607
|
1 725
|
|
| PP&E Net |
12
|
14
|
56
|
102
|
99
|
91
|
83
|
6
|
3
|
2
|
2
|
2
|
2
|
3
|
3
|
6
|
11
|
34
|
116
|
127
|
156
|
146
|
347
|
592
|
|
| PP&E Gross |
12
|
14
|
56
|
102
|
99
|
91
|
83
|
6
|
3
|
2
|
2
|
2
|
2
|
3
|
3
|
6
|
11
|
34
|
116
|
127
|
156
|
146
|
347
|
592
|
|
| Accumulated Depreciation |
8
|
11
|
14
|
19
|
27
|
38
|
46
|
39
|
37
|
37
|
35
|
34
|
28
|
29
|
27
|
26
|
28
|
28
|
34
|
42
|
52
|
66
|
83
|
107
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
37
|
36
|
37
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
21
|
6
|
4
|
0
|
1
|
0
|
38
|
83
|
44
|
247
|
216
|
356
|
265
|
624
|
402
|
849
|
864
|
|
| Other Long-Term Assets |
3
|
4
|
27
|
103
|
105
|
105
|
11
|
10
|
6
|
6
|
4
|
4
|
4
|
5
|
5
|
5
|
5
|
6
|
3
|
326
|
320
|
331
|
412
|
501
|
|
| Total Assets |
346
N/A
|
267
-23%
|
555
+108%
|
519
-6%
|
483
-7%
|
390
-19%
|
277
-29%
|
118
-57%
|
71
-40%
|
144
+104%
|
138
-4%
|
196
+42%
|
155
-21%
|
243
+57%
|
475
+95%
|
365
-23%
|
818
+124%
|
993
+21%
|
1 306
+31%
|
1 735
+33%
|
2 073
+19%
|
2 369
+14%
|
3 251
+37%
|
3 719
+14%
|
|
| Liabilities | |||||||||||||||||||||||||
| Accounts Payable |
2
|
2
|
1
|
5
|
3
|
3
|
4
|
2
|
2
|
1
|
1
|
1
|
0
|
0
|
3
|
5
|
6
|
38
|
46
|
98
|
143
|
236
|
318
|
303
|
|
| Accrued Liabilities |
16
|
22
|
55
|
20
|
18
|
12
|
22
|
11
|
6
|
9
|
9
|
8
|
8
|
12
|
19
|
21
|
48
|
34
|
73
|
81
|
100
|
129
|
163
|
199
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
409
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
2
|
3
|
4
|
7
|
6
|
5
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
169
|
170
|
0
|
|
| Other Current Liabilities |
5
|
6
|
50
|
28
|
7
|
0
|
3
|
14
|
12
|
43
|
38
|
7
|
4
|
4
|
4
|
4
|
1
|
15
|
38
|
8
|
4
|
3
|
4
|
6
|
|
| Total Current Liabilities |
25
|
33
|
110
|
60
|
34
|
20
|
30
|
26
|
20
|
53
|
47
|
16
|
12
|
16
|
26
|
30
|
54
|
88
|
565
|
187
|
246
|
538
|
655
|
508
|
|
| Long-Term Debt |
4
|
5
|
33
|
60
|
54
|
49
|
109
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
370
|
389
|
0
|
318
|
335
|
0
|
0
|
0
|
|
| Other Liabilities |
8
|
5
|
21
|
6
|
6
|
6
|
19
|
55
|
47
|
72
|
31
|
26
|
23
|
19
|
25
|
20
|
21
|
36
|
104
|
104
|
118
|
123
|
365
|
621
|
|
| Total Liabilities |
36
N/A
|
42
+18%
|
164
+287%
|
125
-23%
|
93
-26%
|
75
-19%
|
158
+111%
|
81
-48%
|
67
-18%
|
125
+87%
|
78
-37%
|
42
-47%
|
34
-18%
|
34
N/A
|
50
+47%
|
50
0%
|
446
+787%
|
512
+15%
|
669
+31%
|
609
-9%
|
699
+15%
|
661
-5%
|
1 019
+54%
|
1 129
+11%
|
|
| Equity | |||||||||||||||||||||||||
| Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
107
|
202
|
232
|
278
|
300
|
407
|
615
|
703
|
754
|
762
|
725
|
720
|
766
|
826
|
915
|
1 056
|
1 199
|
1 178
|
1 133
|
725
|
636
|
407
|
157
|
29
|
|
| Additional Paid In Capital |
420
|
424
|
622
|
674
|
692
|
722
|
734
|
742
|
757
|
782
|
785
|
874
|
886
|
1 035
|
1 341
|
1 371
|
1 573
|
1 660
|
1 768
|
1 850
|
2 011
|
2 122
|
2 382
|
2 555
|
|
| Other Equity |
2
|
2
|
1
|
2
|
2
|
0
|
0
|
2
|
1
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
2
|
2
|
1
|
2
|
2
|
8
|
7
|
6
|
|
| Total Equity |
310
N/A
|
224
-28%
|
391
+74%
|
394
+1%
|
390
-1%
|
315
-19%
|
119
-62%
|
37
-69%
|
4
-89%
|
19
+383%
|
60
+211%
|
154
+157%
|
120
-22%
|
209
+73%
|
425
+103%
|
315
-26%
|
372
+18%
|
481
+29%
|
637
+32%
|
1 126
+77%
|
1 374
+22%
|
1 708
+24%
|
2 232
+31%
|
2 590
+16%
|
|
| Total Liabilities & Equity |
346
N/A
|
267
-23%
|
555
+108%
|
519
-6%
|
483
-7%
|
390
-19%
|
277
-29%
|
118
-57%
|
71
-40%
|
144
+104%
|
138
-4%
|
196
+42%
|
155
-21%
|
243
+57%
|
475
+95%
|
365
-23%
|
818
+124%
|
993
+21%
|
1 306
+31%
|
1 735
+33%
|
2 073
+19%
|
2 369
+14%
|
3 251
+37%
|
3 719
+14%
|
|
| Shares Outstanding | |||||||||||||||||||||||||
| Common Shares Outstanding |
30
|
31
|
35
|
37
|
37
|
38
|
38
|
39
|
44
|
55
|
55
|
66
|
67
|
77
|
86
|
87
|
89
|
91
|
92
|
94
|
95
|
97
|
99
|
99
|
|
Switch to:
Switch to:
See Also
Discover More
